APTO - Aptose Biosciences Inc.
IEX Last Trade
0.2112
-0.009 -4.167%
Share volume: 1,337
Last Updated: Mon 13 Jan 2025 07:22:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.44%
PREVIOUS CLOSE
CHG
CHG%
$0.22
-0.01
-4.00%
Fundamental analysis
8%
Profitability
8%
Dept financing
22%
Liquidity
24%
Performance
0%
Performance
5 Days
3.19%
1 Month
13.99%
3 Months
-42.04%
6 Months
-68.57%
1 Year
-90.13%
2 Year
-68.57%
Key data
Stock price
$0.21
DAY RANGE
$0.21 - $0.21
52 WEEK RANGE
$0.18 - $2.42
52 WEEK CHANGE
-$90.13
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: William G. Rice
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.
Recent news